Dr. Figlin on remaining questions from KEYNOTE-564 trial of adjuvant pembrolizumab in RCC
Robert A. Figlin, MD, deputy director, Cedars-Sinai Cancer, discusses remaining questions from the phase 3 KEYNOTE-564 trial, which was presented at the 2021 ASCO Annual Meeting (LBA5). The study findings showed that adjuvant pembrolizumab (Keytruda) led to a significant reduction in the risk of disease recurrence or death versus placebo in patients with clear cell renal cell carcinoma. In the video, Figlin shares his expert observations on important questions that still remain, despite the positive results of the trial.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
